HK81097A - Water soluble camptothecin analogs - Google Patents

Water soluble camptothecin analogs

Info

Publication number
HK81097A
HK81097A HK81097A HK81097A HK81097A HK 81097 A HK81097 A HK 81097A HK 81097 A HK81097 A HK 81097A HK 81097 A HK81097 A HK 81097A HK 81097 A HK81097 A HK 81097A
Authority
HK
Hong Kong
Prior art keywords
alkyl
hydrogen
water soluble
ch2nh2
formyl
Prior art date
Application number
HK81097A
Other languages
English (en)
Inventor
Jeffrey Charles Boehm
Randall Keith Johnson
Sidney Michael Hecht
William Dennis Kingsbury
Kenneth George Holden
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of HK81097A publication Critical patent/HK81097A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Semiconductor Lasers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK81097A 1987-12-01 1997-06-12 Water soluble camptothecin analogs HK81097A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12714887A 1987-12-01 1987-12-01

Publications (1)

Publication Number Publication Date
HK81097A true HK81097A (en) 1997-06-20

Family

ID=22428545

Family Applications (1)

Application Number Title Priority Date Filing Date
HK81097A HK81097A (en) 1987-12-01 1997-06-12 Water soluble camptothecin analogs

Country Status (25)

Country Link
US (1) US5004758A (xx)
EP (1) EP0321122B1 (xx)
JP (1) JPH0633268B2 (xx)
KR (1) KR930009357B1 (xx)
CN (3) CN1027265C (xx)
AT (1) ATE143368T1 (xx)
AU (1) AU612735B2 (xx)
CA (1) CA1308102C (xx)
CY (1) CY2017A (xx)
DE (2) DE19775017I2 (xx)
DK (1) DK173034B1 (xx)
ES (1) ES2094721T3 (xx)
FI (1) FI89923C (xx)
GR (1) GR3021990T3 (xx)
HK (1) HK81097A (xx)
IE (1) IE74873B1 (xx)
IL (1) IL88517A (xx)
LU (2) LU90026I2 (xx)
MX (1) MX9203744A (xx)
NL (1) NL970017I2 (xx)
NO (2) NO170487C (xx)
NZ (1) NZ227124A (xx)
PT (1) PT89111B (xx)
SG (1) SG66254A1 (xx)
ZA (1) ZA888938B (xx)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5122526A (en) * 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5227380A (en) * 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US5106742A (en) * 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US5180722A (en) * 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US5049668A (en) * 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
JP2684104B2 (ja) * 1990-02-09 1997-12-03 株式会社ヤクルト本社 新規なカンプトテシン誘導体
WO1992005785A1 (en) * 1990-09-28 1992-04-16 Smithkline Beecham Corporation Water soluble camptothecin analogues, processes and methods
US5883255A (en) * 1990-10-31 1999-03-16 Smithkline Beecham Corporation Substituted indolizino 1,2-b!quinolinones
DE69233773D1 (de) * 1991-02-21 2009-11-19 Smithkline Beecham Corp Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs
KR930702985A (ko) * 1991-02-21 1993-11-29 스튜어트 알.슈터 식도암의 치료
DE69232852T2 (de) * 1991-02-21 2003-09-04 Smithkline Beecham Corp., Philadelphia Verwendung von topotecan in der behandlung von nichtkleinzelligen lungenkarzinomen
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
ES2086643T3 (es) * 1991-10-29 1996-07-01 Glaxo Wellcome Inc Derivados de camptotecina solubles en agua.
AU671605B2 (en) * 1991-11-15 1996-09-05 Smithkline Beecham Corporation Combination chemotherapy
AU2394392A (en) * 1991-12-10 1993-07-19 Smithkline Beecham Corporation Treatment of colorectal cancer
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
US5446047A (en) * 1992-07-23 1995-08-29 Sloan-Kettering Institute For Cancer Research Camptothecin analogues
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
JPH08502044A (ja) * 1992-08-21 1996-03-05 デイナ・フアーバー・キヤンサー・インステイテユート ヒトウイルス感染の治療
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5674872A (en) * 1993-08-20 1997-10-07 Smithkline Beecham Corporation Treatment of ovarian cancer
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
CA2174350A1 (en) * 1993-10-20 1995-04-27 Richard B. Greenwald 2'- and/or 7- substituted taxoids
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
WO1995029677A1 (en) * 1994-04-28 1995-11-09 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin or 7-ethyl camptothecin
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US6504029B1 (en) * 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5663177A (en) * 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5670500A (en) * 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5942386A (en) * 1995-06-07 1999-08-24 Thomas Jefferson University Anti-fungal agents and methods of identifying and using the same
AU7732996A (en) * 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
WO1998007727A1 (en) * 1996-08-19 1998-02-26 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
US6013505A (en) * 1996-10-08 2000-01-11 Smithkline Beecham Corporation Topoisomerase I
US5962303A (en) 1996-10-15 1999-10-05 Smithkline Beecham Corporation Topoisomerase III
US6025156A (en) * 1996-10-15 2000-02-15 Smithkline Beecham Corporation Topoisomerase III
US6559309B2 (en) 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
ATE329903T1 (de) * 1997-02-14 2006-07-15 Bionumerik Pharmaceuticals Inc Hochgradig lipophile camptothecin-derivate
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US6046209A (en) * 1997-05-27 2000-04-04 Smithkline Beecham Corporation Water soluble camptothecin analogs
TW458974B (en) * 1997-07-17 2001-10-11 Kuraray Co Process for producing chromans
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
EE04264B1 (et) * 1998-08-05 2004-04-15 Aventis Pharma S.A. Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
FR2801309B1 (fr) * 1999-11-18 2002-01-04 Adir Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
BR0108728A (pt) 2000-02-28 2003-12-30 Aventis Pharma Sa Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AR027687A1 (es) * 2000-03-22 2003-04-09 Yakult Honsha Kk Procedimiento para preparar camptotecina
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
WO2002034244A2 (en) 2000-10-27 2002-05-02 Aventis Pharma S.A. A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
EP1335974A2 (en) * 2000-11-14 2003-08-20 Emerald Biostructures Inc. Crystal compositions comprising topoisomerase i
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US7462601B2 (en) * 2002-03-26 2008-12-09 Tsutomu Kagiya Ameliorant for chemical treatment of cancer
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
WO2004055020A1 (en) * 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Process for the direct preparation of 5-alkoxy and 5-acyloxy analogues of campthothecins or mappicene ketones
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
WO2004087715A1 (en) * 2003-03-31 2004-10-14 Council Of Scientific And Industrial Research Process for preparing topotecan from 10-hydroxy-4-(s) camptothecin
CN100406460C (zh) * 2003-11-10 2008-07-30 中国科学院上海药物研究所 喜树碱的新衍生物、制备方法和用途
TWI333492B (en) * 2003-11-12 2010-11-21 Smithkline Beecham Cork Ltd Crystalline topotecan hydrochloride product and preparation thereof
US7422741B2 (en) 2004-03-05 2008-09-09 Vegenics Limited VEGFR-3 fusion proteins
RU2408387C2 (ru) 2004-04-27 2011-01-10 Веллстат Байолоджикс Корпорейшн Лечение злокачественного новообразования с применением вирусов и камптотецинов
US20050267141A1 (en) 2004-05-28 2005-12-01 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives
US20050272757A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
US7122700B2 (en) * 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
WO2012050591A1 (en) 2010-10-15 2012-04-19 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
US20090104254A1 (en) 2004-12-22 2009-04-23 Rutgers, The State University Of New Jersey Controlled Release Hydrogels
US20080161251A1 (en) 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds
WO2006090931A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の抗癌剤との新規併用
AU2006270297B2 (en) * 2005-07-14 2013-01-17 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
EP1943253A1 (en) * 2005-10-10 2008-07-16 Cipla Limited Novel crystalline forms
TW200731990A (en) * 2005-12-16 2007-09-01 Sonus Pharma Inc Lipophilic anticancer drug compounds, compositions, and related methods
US7547785B2 (en) 2005-12-26 2009-06-16 Dr. Reddy's Laboratories Limited Process for preparing topotecan
WO2007085370A1 (en) * 2006-01-25 2007-08-02 Heidelberg Pharma Ag 9-(dimethylamino)-methyl-10-hydroxy-camptothecin lipidester derivatives
CN101033230B (zh) * 2006-03-10 2010-12-08 中国科学院上海药物研究所 一类喜树碱衍生物及其应用
AU2007232206B2 (en) 2006-03-30 2013-04-04 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
US20110028536A1 (en) * 2006-08-18 2011-02-03 Gjerset Ruth A Methods and compositions for topoisomerase i modulated tumor suppression
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US7977483B2 (en) * 2007-04-11 2011-07-12 Scinopharm Taiwan, Ltd. Process for making topotecan
US20080255175A1 (en) * 2007-04-16 2008-10-16 Lam Marina K Anti-cancer agents, compositions and methods of treating cancers
CA2684599C (en) * 2007-04-19 2013-07-02 Scinopharm Taiwan Ltd. Crystalline forms of topotecan hydrochloride and processes for making the same
US8026249B2 (en) * 2007-09-14 2011-09-27 Deutena Pharmaceuticals, Inc. Deuterium-enriched topotecan
ITMI20072268A1 (it) 2007-12-04 2009-06-05 Antibioticos Spa Polimorfi cristallini di topotecan cloridrato con elevato grado di purezza e metodi per la loro preparazione
WO2009145282A1 (ja) * 2008-05-29 2009-12-03 メルシャン株式会社 カンプトテシン誘導体の製造方法
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8551973B2 (en) * 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
EP3222628A1 (en) * 2008-12-23 2017-09-27 Gilead Pharmasset LLC Nucleoside phosphoramidates
WO2011116026A2 (en) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibitors of beta integrin-g protein alpha subunit binding interactions
PT3290428T (pt) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
RU2447076C1 (ru) * 2010-12-09 2012-04-10 Закрытое Акционерное Общество "Фарм-Синтез" Способ получения топотекана
EP2654754B1 (en) 2010-12-17 2016-12-21 Novartis AG Combination for treating osteosarcoma, rhabdomyosarcoma and neuroblastoma
US20140371258A1 (en) 2010-12-17 2014-12-18 Nektar Therapeutics Water-Soluble Polymer Conjugates of Topotecan
EP2655401B1 (en) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
JP2014504638A (ja) 2011-02-01 2014-02-24 グラクソスミスクライン インテレクチュアル プロパティ リミテッド 組合せ
RS57350B1 (sr) 2011-10-03 2018-08-31 Mx Adjuvac Ab Nanočestice, postupak dobijanja i njihova primena kao nosača amfipatičnih ili hidrofobnih molekula u medicini, uključujući i terapiju kancera, kao i prehrambenih jedinjenja
PL235836B1 (pl) * 2012-10-25 2020-11-02 Inst Chemii Organicznej Polskiej Akademii Nauk Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie
CN103113381B (zh) * 2013-02-26 2014-12-10 大连理工大学 系列水溶性羟基喜树碱环烷胺醇衍生物及其制法与用途
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
EP3250609A4 (en) 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
CN108135917B (zh) 2015-09-25 2021-07-09 Zy医疗 基于包含多糖-维生素缀合物的颗粒的药物制剂
BR112018068565A2 (pt) 2016-03-15 2019-02-12 Oryzon Genomics, S.A. combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
SI3458052T1 (sl) * 2016-05-17 2020-04-30 Scandion Oncology A/S Kombinirano zdravljenje raka
AU2018314227A1 (en) 2017-08-07 2020-02-06 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
WO2020191342A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
CA3136496A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
AU2020266083A1 (en) 2019-04-30 2021-09-23 Instituto de Medicina Molecular João Lobo Antunes Rank pathway inhibitors in combination with CDK inhibitors
US20220305081A1 (en) 2019-06-24 2022-09-29 Amgen Inc. Inhibitions of sirp-gamma for cancer treatment
EP4025206A1 (en) 2019-09-02 2022-07-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating pax6- deficiency related disease
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
CN116478174A (zh) * 2022-07-29 2023-07-25 杭州爱科瑞思生物医药有限公司 喜树碱衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4342776A (en) * 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
JPS58134095A (ja) * 1982-02-05 1983-08-10 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS58154584A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd ５位ヒドロキシ置換カンプトテシン誘導体の製造法
JPS5951289A (ja) * 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体
JPS59227884A (ja) * 1983-06-09 1984-12-21 Yakult Honsha Co Ltd 新規な７−ヒドロキシアルキルカンプトテシン誘導体
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4775759A (en) * 1984-11-27 1988-10-04 The United States Of America As Represented By The Department Of Health And Human Services Synthesis and utilization of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy 6β-fluoromorphinans (foxy and cyclofoxy) as (18F)-labeled opioid ligands for position emission transaxial tomography (PETT)
US4820816A (en) * 1985-08-02 1989-04-11 President And Fellows Of Harvard College 3-trifuoromethylsulfonyloxy-substituted 1-carbacephalosporins as intermediates for antibiotics
JPH0615546B2 (ja) * 1986-02-24 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
JP3431931B2 (ja) * 1992-07-16 2003-07-28 旭電化工業株式会社 銅及び銅合金の表面処理方法

Also Published As

Publication number Publication date
NO170487B (no) 1992-07-13
CY2017A (en) 1998-02-20
DK663688D0 (da) 1988-11-28
CN1087637A (zh) 1994-06-08
MX9203744A (es) 1992-09-01
DE19775017I2 (de) 2002-11-07
KR890009934A (ko) 1989-08-05
EP0321122A3 (en) 1990-12-27
NL970017I2 (nl) 1997-09-01
NO1998003I1 (no) 1998-01-15
JPH01186893A (ja) 1989-07-26
FI885569A (fi) 1989-06-02
EP0321122B1 (en) 1996-09-25
KR930009357B1 (ko) 1993-09-28
CN1027265C (zh) 1995-01-04
ATE143368T1 (de) 1996-10-15
CN1083817A (zh) 1994-03-16
DK173034B1 (da) 1999-11-29
DE3855575D1 (de) 1996-10-31
IL88517A (en) 1994-10-07
PT89111A (pt) 1989-12-29
NZ227124A (en) 1991-12-23
IE883576L (en) 1989-06-01
FI89923C (fi) 1993-12-10
LU90053I2 (fr) 1997-07-01
EP0321122A2 (en) 1989-06-21
LU90026I2 (fr) 1997-04-22
FI885569A0 (fi) 1988-11-30
DK663688A (da) 1989-06-02
ZA888938B (en) 1990-03-28
CA1308102C (en) 1992-09-29
JPH0633268B2 (ja) 1994-05-02
CN1034724A (zh) 1989-08-16
IL88517A0 (en) 1989-06-30
SG66254A1 (en) 1999-07-20
NO885352L (no) 1989-06-02
NO885352D0 (no) 1988-11-30
AU612735B2 (en) 1991-07-18
PT89111B (pt) 1994-01-31
CN1037574C (zh) 1998-03-04
CN1035380C (zh) 1997-07-09
ES2094721T3 (es) 1997-02-01
GR3021990T3 (en) 1997-03-31
DE3855575T2 (de) 1997-03-20
AU2639488A (en) 1989-06-01
NL970017I1 (nl) 1997-06-02
NO170487C (no) 1992-10-21
FI89923B (fi) 1993-08-31
IE74873B1 (en) 1997-08-13
US5004758A (en) 1991-04-02

Similar Documents

Publication Publication Date Title
HK81097A (en) Water soluble camptothecin analogs
HUT47110A (en) Process for producing pyrazolopyridine derivatives
HUT53368A (en) Process for producing pyrazolo-pyridine derivatives and pharmaceutical compositions containing them
AU6216886A (en) Substituted 2-cyano-2-phenyl ethyl-amine
EP0186023A3 (en) Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
HK1018783A1 (en) BENZO[C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5 α-REDUCTASES INHIBITORS
DE3567651D1 (en) Novel 1,5-benzothiazepine derivative, processes for preparing the same and pharmaceutical compositions
NZ216334A (en) Spiro imidazolone derivatives and pharmaceutical composition
ATE30724T1 (de) Cephalosporinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten.
DE3665593D1 (en) Peptide immunostimulants
EP0541726A4 (en) Growth factor compositions, preparation and use
EP0115920A3 (en) Pyrazino(2',3'-3,4)pyrido(1,2-a) indole derivatives
ES8707939A1 (es) Procedimiento para preparar derivados de n-carboxialquil-2--oxo-3-diaril-5,6-triazinas
ES8207176A1 (es) Procedimiento para la preparacion de derivados de la hexahi-dro-2,3,3,4,5.6-1h-indol(3,2,1-de)(naftiridina-1,5)

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20081129